Streetbeat News

MGX

Metagenomi Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

1.85

Mkt cap

65M

Volume

562K

High

1.94

P/E Ratio

-0.73

52-wk high

11.86

Low

1.69

Div yield

N/A

52-wk low

1.61

Rosen Law Firm is urging investors in Metagenomi, Inc. (NASDAQ: MGX) to secure legal counsel before the November 25, 2024 deadline for a securities class action related to the company's IPO in February 2024.

Portfolio Pulse from

November 19, 2024 | 6:45 pm

Glancy Prongay & Murray LLP has announced a deadline for investors to file a lead plaintiff motion in a class action lawsuit against Metagenomi, Inc. The lawsuit concerns investors who acquired Metagenomi securities related to its February 2024 IPO.

Portfolio Pulse from

November 19, 2024 | 6:45 pm

Levi & Korsinsky has filed a securities class action lawsuit on behalf of Metagenomi, Inc. (NASDAQ:MGX) shareholders. Investors who suffered losses can seek potential recovery under federal securities laws.

Portfolio Pulse from

November 19, 2024 | 5:45 pm

Metagenomi, Inc. (NASDAQ:MGX) is facing a lawsuit for securities law violations. Investors who have suffered losses are encouraged to contact Levi & Korsinsky before November 25, 2024, to discuss potential recovery options.

Portfolio Pulse from

November 19, 2024 | 12:30 pm

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Metagenomi, Inc. (NASDAQ:MGX) and certain officers for alleged violations of federal securities laws. The lawsuit targets those who acquired Metagenomi securities during its IPO period from February 9, 2024, to May 1, 2024.

Portfolio Pulse from

November 19, 2024 | 12:15 pm

Levi & Korsinsky has notified investors of Metagenomi, Inc. (NASDAQ:MGX) about a class action lawsuit and an upcoming deadline. Investors who suffered losses can learn about potential recovery under federal securities laws.

Portfolio Pulse from

November 19, 2024 | 4:00 am

A class action lawsuit has been filed against Metagenomi, Inc. (NASDAQ: MGX) by Bragar Eagel & Squire, P.C. The lawsuit is on behalf of investors who acquired Metagenomi securities during its IPO period from February 9, 2024, to May 1, 2024. Investors have until November 25, 2024, to apply as lead plaintiffs.

Portfolio Pulse from

November 19, 2024 | 2:15 am

Levi & Korsinsky has notified shareholders of Metagenomi, Inc. (NASDAQ:MGX) about a class action lawsuit and an upcoming deadline for potential recovery under federal securities laws.

Portfolio Pulse from

November 19, 2024 | 2:00 am

Faruqi & Faruqi, LLP is investigating claims on behalf of investors in Metagenomi. Investors who have suffered losses exceeding $50,000 are encouraged to contact the firm for potential legal action.

Portfolio Pulse from

November 19, 2024 | 1:30 am

Levi & Korsinsky is inviting investors in Metagenomi, Inc. (NASDAQ:MGX) who suffered losses to contact them before November 25, 2024, to discuss potential recovery under federal securities laws.

Portfolio Pulse from

November 19, 2024 | 12:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.